drugset / Trial / NCT00332254

Study to Prevent Cartilage Damage Following Acute Knee Injury.

NCT00332254

Phase 1/2 Completed 10 enrolled Duke University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Individuals who have had a severe knee injury have an increased risk of developing arthritis of the knee and at a much earlier age than would otherwise be expected. The swelling and inflammation that occur after injury are believed to be responsible for this cartilage damage. The cartilage (material that provides a cushion in the knee) is the primary protection from what is called degenerative arthritis or osteoarthritis. We hope to reduce this swelling and prevent the damage to cartilage that occurs after injury by injecting a medication that blocks one of the proteins responsible for inflammation and cartilage breakdown. This protein is called interleukin-1 and can be inhibited by an interleukin-1 receptor antagonist called anakinra. Anakinra will be injected directly into the injured knee and response to the injection will be measured by symptoms and analysis of cartilage breakdown in the knee fluid and blood.

Timeline

Start
2006-03
Primary completion
2007-06
Completion
2007-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Anakinra Protein / enzyme biologic 150 mg Other

Indications